Form 4: Surrozen Inc. Director Acquires Stock Options

Mace Rothenberg, a Director at Surrozen, Inc., acquired 5,550 stock options with an exercise price of $30.14 on May 13, 2026.

Summary

• Mace Rothenberg, a Director at Surrozen, Inc., acquired 5,550 stock options on May 13, 2026.
• The options have an exercise price of $30.14 and are exercisable starting May 13, 2027, with an expiration date of May 12, 2036.
• These options vest and become exercisable on the anniversary of the grant date, contingent upon continuous service as a director.
• Following this transaction, Rothenberg beneficially owns 5,550 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard grant of stock options to a director, which is typical compensation. The value is entirely dependent on future stock performance.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The long expiration date of the options (May 12, 2036) suggests a long-term commitment and potential for significant future value if the stock price increases.

Negatives

• The exercise price of $30.14 is significantly higher than the current market price, indicating that the options will only be profitable if the stock price substantially increases.

Risks

• The vesting of options is contingent on continuous service as a director, meaning any departure from the board would forfeit unvested options.
• The value of the acquired options is directly tied to the future performance of Surrozen, Inc.'s stock price, which is subject to market volatility and company-specific risks.

Future Outlook

The future outlook for the acquired stock options is dependent on Surrozen, Inc.'s stock performance. The options are exercisable from May 13, 2027, and expire on May 12, 2036. Their value will be realized if the stock price exceeds the $30.14 exercise price.

Industry Context

StockSavvy.ai notes that director grants of stock options are a common form of executive compensation in the biotechnology and pharmaceutical sectors, aligning management's interests with those of shareholders. The exercise price of $30.14 suggests an expectation of significant future stock appreciation, a common theme in growth-oriented companies within this industry.

Stakeholder Impact

• Shareholders: The grant of options to directors is a standard practice, but its ultimate impact depends on the company's stock performance. If the stock price rises above the exercise price, it could dilute existing shareholder value upon exercise, but also aligns director incentives with shareholder interests.
• Employees: While not directly impacted by this specific transaction, the company's overall stock performance, influenced by management's incentives, affects employee stock options and morale.
• Management: Directors like Mace Rothenberg are incentivized to drive company performance to realize the value of their stock options.

Next Steps

• Mace Rothenberg will continue to serve as a director, subject to continuous service requirements for option vesting.
• The options will become exercisable on May 13, 2027, and can be exercised until their expiration on May 12, 2036, provided the stock price is above the exercise price.

Key Dates

Keywords

Surrozen Inc., SRZN, Form 4, Stock Options, Director, Beneficial Ownership, Securities Exchange Act, SEC Filing